122 related articles for article (PubMed ID: 10674348)
1. Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys.
Sola MC; Christensen RD; Hutson AD; Tarantal AF
Pediatr Res; 2000 Feb; 47(2):208-14. PubMed ID: 10674348
[TBL] [Abstract][Full Text] [Related]
2. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
[TBL] [Abstract][Full Text] [Related]
3. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
[TBL] [Abstract][Full Text] [Related]
4. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
[TBL] [Abstract][Full Text] [Related]
5. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans.
De Boer RH; Roskos LK; Cheung E; Fox S; Basser RL; Marty J; Begley CG; Cebon J
Growth Factors; 2000; 18(3):215-26. PubMed ID: 11334057
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin therapy increases platelet yields in healthy platelet donors.
Kuter DJ; Goodnough LT; Romo J; DiPersio J; Peterson R; Tomita D; Sheridan W; McCullough J
Blood; 2001 Sep; 98(5):1339-45. PubMed ID: 11520780
[TBL] [Abstract][Full Text] [Related]
10. A mild transient decrease of peripheral red blood cell counts induced by a suprapharmacological dose of pegylated human megakaryocyte growth and development factor in rats.
Harada K; Ide Y; Tazunoki Y; Imai A; Yanagida M; Kikuchi Y; Imai A; Ishii H; Kawahara J; Izumi H; Kusaka M; Tokiwa T
J Pharm Pharmacol; 1999 Jul; 51(7):841-6. PubMed ID: 10467960
[TBL] [Abstract][Full Text] [Related]
11. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
Basser RL
Stem Cells; 1998; 16 Suppl 2():225-9. PubMed ID: 11012194
[TBL] [Abstract][Full Text] [Related]
12. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
Fanucchi M; Glaspy J; Crawford J; Garst J; Figlin R; Sheridan W; Menchaca D; Tomita D; Ozer H; Harker L
N Engl J Med; 1997 Feb; 336(6):404-9. PubMed ID: 9010146
[TBL] [Abstract][Full Text] [Related]
13. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
Molineux G; Hartley C; McElroy P; McCrea C; McNiece IK
Blood; 1996 Jul; 88(1):366-76. PubMed ID: 8704197
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
Bolwell B; Vredenburgh J; Overmoyer B; Gilbert C; Chap L; Menchaca DM; Cruickshank S; Glaspy J
Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
[TBL] [Abstract][Full Text] [Related]
15. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor.
Harker LA; Marzec UM; Novembre F; Sundell IB; Waller EK; Karpatkin S; McClure HM; Kelly AB; Stead RB
Blood; 1998 Jun; 91(12):4427-33. PubMed ID: 9616135
[TBL] [Abstract][Full Text] [Related]
16. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
[TBL] [Abstract][Full Text] [Related]
17. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
Geissler K; Yin JA; Ganser A; Sanz MA; Szer J; Raghavachar A; Hoelzer D; Martinez C; Taylor K; Kanz L; To LB; Archimbaud E
Ann Hematol; 2003 Nov; 82(11):677-83. PubMed ID: 14530872
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
Goodnough LT; Kuter DJ; McCullough J; Slichter SJ; DiPersio J; Romo J; Peterson R; Smith KJ; Raife T; Tomita D; Armstrong S
Blood; 2001 Sep; 98(5):1346-51. PubMed ID: 11520781
[TBL] [Abstract][Full Text] [Related]
19. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
Ide Y; Harada K; Imai A; Yanagida M
Int J Hematol; 1999 Aug; 70(2):91-6. PubMed ID: 10497847
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
Farese AM; MacVittie TJ; Roskos L; Stead RB
Stem Cells; 2003; 21(1):79-89. PubMed ID: 12529554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]